The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Progress in CHIP/CCUS: how overlapping lesions may change patient management
Zhuoer Xie, MD, MS, Moffitt Cancer Center, Tampa, FL, discusses recent advances in the assessment of clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS). Dr Xie emphasizes the importance of evaluating both somatic mutations and mosaic chromosomal alterations, as overlapping lesions appear to confer a higher risk of hematologic malignancies than either abnormality alone. She highlights that considering overlapping lesions may help guide patient monitoring and identify patients for clinical trials. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
